[00:02] a shocker. One of the most popular supplements marketed as anti-aging and that is often sold over the counter was just tested in a clinical trial and the results are pretty concerning. So, there is a molecule we all have in our bodies [00:15] mitochondrial metabolism, for mitochondrial energy production functions. It has this long name, it's called nicotinamide adenine dinucleotide [00:29] or NAD for short. And this is what's called a coenzyme. So, it participates in chemical reactions in your body and helps a number of reactions take place. helps a number of reactions take place. But, NAD levels naturally drop with age [00:43] and also in some neurodegenerative diseases like Alzheimer's and Parkinson's, NAD levels are lower as well. So, this idea was born, maybe if well. So, this idea was born, maybe if we add back NAD, if we raise NAD levels [00:57] diseases maybe we can improve their cellular functions and their health overall. And a number of studies back up this idea. So, if you take cells from someone with Parkinson's for example, you isolate [01:11] they tend to have a number of mitochondrial defects. And if you raise their NAD levels in a petri dish, in a lab setting, you can rescue some of those problems, you can improve their cellular function. You can [01:24] also create a model of Parkinson's disease for example in lab animals. So, a fruit fly for example, I did a lot of these experiments during my PhD, you can create genetic mutations in these flies in the same genes that are mutated in a [01:38] lot of patients with Parkinson's disease and studies have shown these flies have motor issues. And if you raise the NAD levels in these animals, a lot of the cellular problems get better and their motor function in [01:51] general improves. So, these are obviously very exciting results. Parkinson's doesn't have a cure, there's medical treatment, there's medication, but there's no cure for Parkinson's. So, maybe NAD and NAD raising agents were [02:06] going to be a big step in that direction. So, scientists moved on to experimenting in humans, clinical trials. This is the right progression it. And initially, those trials also seemed [02:18] promising. There are two small randomized trials in human beings with between 20 and per trial and lasting about a month. And looking at people with early stage Parkinson's. So, they've been diagnosed [02:33] recently. The disease hasn't progressed much yet. And then looking at the effect of raising NAD levels in those patients. NAD directly, it doesn't really work. It doesn't [02:46] really raise NAD levels in the body. So, what's usually done is people take precursors of NAD. One of the most famous ones and commonly used is called nicotinamide riboside or NR. So, in these two trials, they gave them this NR [03:01] agent and in both trials, they showed that the NAD levels went up. And in both trials, there was a suggestion that their Parkinson's disease symptoms might be improving at least in a subset of the participants getting the NR pill. [03:17] compared to a placebo. So, it's a dummy pill that doesn't have NR, the participants don't know which one they're getting. So, this is exactly the right way to do it. You start with small human trials mainly to look at safety. [03:33] So, you want to look at whether the drug or the the agent causes any right away. And those two trials, NR seemed pretty safe. So, scientists moved on to a larger trial. And that just got released this month, about 400 [03:50] patients again with early stage Parkinson's disease, under 2 years uh post diagnosis, and they received either NR, a dose of 1 g a day, two 500 mg [04:02] doses, or placebo. And they were followed for 1 year. So, much larger in scale, a lot more people, and much longer as well this is a double-blind, placebo-randomized [04:15] trial. So, the participants are distributed randomly into the two groups, and they don't know which one which of the pills they're getting. And the investigators that are directly interacting with the patients also don't [04:27] know who's on what. So, it eliminates a lot of the biases. Again, they showed NR was effective at raising NAD levels, at least in the blood of the participants. The levels in the brain was less clear. Some questions there. And the bottom [04:41] line from this trial is their Parkinson's disease symptoms, if they have a scale where they rate overall Parkinson's disease symptoms. That didn't change on the placebo comparing beginning to the end of the [04:56] but on the group receiving the NR, it actually got a little bit worse. The difference is not large. It was a modest difference. It was below the threshold that's considered clinically important, [05:08] So, it was a statistically significant worsening of Parkinson's symptoms on the folks getting the NR. So, those were total Parkinson's symptoms, a scale that kind of kind of captures everything. Then they looked at subtypes and [05:22] non-motor symptoms. So, that's things like mood, attention, memory, fatigue. Those non-motor symptoms as a whole also got worse on the folks getting NR. The exact reason is not understood. Maybe NR or NAD interacts with Parkinson's [05:38] medications, or maybe it's having some other effect on the nervous system. Now, it's important not to overclaim. This trial does not mean that if you take Parkinson's. Remember, they already had the disease at a very early stage and [05:52] we're seeing a modest worsening of the symptoms. Also, this doesn't mean that NR can't be shown in the future to be beneficial in other contexts. People who don't have Parkinson's or other disease contexts. All of that needs to [06:06] be investigated. But this raises obvious concerns for a supplement that's sold essentially no supervision, to millions of people. This is a multi-million dollar supplement, NR alone, and it's largely based on hype, [06:20] preliminary results, and animals and cells in a petri dish, and these very short trials that are not powered to look at actual disease outcomes. In science, we move carefully and we move slowly for a reason. Results [06:34] in a petri dish or in a lab animal are not a reason to sell a pill. They're not a reason to pop a pill. Even results in humans that are preliminary very often don't pan out when you properly test things. This happens all the time. [06:46] So, you want to understand what is science and what is hype, what is compelling and what's just marketing. Stay informed. Stay protected. We just published a video where we investigated dozens of popular supplements, including [07:00] NAD supplements and many others. Most did not pass the test. Watch that next right here, and I'll see you in there.